Top

Published in:

Open Access 01-07-2020 | Literatur kommentiert

Zirkulierende HPV-Tumor-DNA als möglicher Biomarker in der Rezidivdiagnostik des HPV-assoziierten Oropharynxkarzinoms

Authors: Dr. med. Alexander Rühle, PD Dr. Dr. med. Nils H. Nicolay

Published in: Strahlentherapie und Onkologie | Issue 7/2020

Auszug

Die prospektive Biomarkerstudie von Chera und Kollegen hatte zum Ziel, den Stellenwert von im Blutplasma zirkulierender HPV-Tumor-DNA zur Diagnose eines Rezidivs bei Patienten mit HPV-positiven Plattenepithelkarzinomen des Oropharynx zu bestimmen [1]. …

Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, Goldman E, Weiss J, Grilley-Olson J, Patel S, Zanation A, Hackman T, Blumberg J, Patel S, Thorp B, Weissler M, Yarbrough W, Sheets N, Mendenhall W, Tan XM, Gupta GP (2020) Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. https://doi.org/10.1200/jco.19.02444 CrossRefPubMedPubMedCentral

Chera BS, Kumar S, Beaty BT, Marron D, Jefferys SR, Green RL, Goldman EC, Amdur R, Sheets N, Dagan R, Hayes DN, Weiss J, Grilley-Olson JE, Zanation AM, Hackman TG, Blumberg JM, Patel S, Weissler MC, Tan X, Parker JS, Mendenhall WM, Gupta GP (2019) Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.Ccr-19-0211 CrossRefPubMedPubMedCentral

Huang SH, Perez-Ordonez B, Liu FF, Waldron J, Ringash J, Irish J, Cummings B, Siu LL, Kim J, Weinreb I, Hope A, Gullane P, Brown D, Shi W, O’Sullivan B (2012) Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82(1):276–283. https://doi.org/10.1016/j.ijrobp.2010.08.031 CrossRefPubMed

Fakhry C, Blackford AL, Neuner G, Xiao W, Jiang B, Agrawal A, Gillison ML (2019) Association of oral human papillomavirus DNA persistence with cancer progression after primary treatment for oral cavity and oropharyngeal squamous cell carcinoma. JAMA Oncol 5(7):985–992. https://doi.org/10.1001/jamaoncol.2019.0439 CrossRefPubMedPubMedCentral

Wang J, Sun H, Zeng Q, Guo X‑J, Wang H, Liu H‑H, Dong Z‑Y (2019) HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD‑1 therapy in head and neck squamous cell carcinoma. Sci Rep 9(1):13404. https://doi.org/10.1038/s41598-019-49771-0 CrossRefPubMedPubMedCentral

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet 17(7):956–965. https://doi.org/10.1016/S1470-2045(16)30066-3 CrossRef

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252 CrossRefPubMedPubMedCentral

Goodwin WJ Jr. (2000) Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl 93):1–18. https://doi.org/10.1097/00005537-200003001-00001 CrossRefPubMed

Han K, Leung E, Barbera L, Barnes E, Croke J, Grappa MAD, Fyles A, Metser U, Milosevic M, Pintilie M, Wolfson R, Zhao Z, Bratman SV (2018) Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation. JCO Precision Oncology 2:1–8. https://doi.org/10.1200/po.18.00152 CrossRefPubMed

Title: Zirkulierende HPV-Tumor-DNA als möglicher Biomarker in der Rezidivdiagnostik des HPV-assoziierten Oropharynxkarzinoms
Authors: Dr. med. Alexander Rühle
PD Dr. Dr. med. Nils H. Nicolay
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 7/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01618-8

At a glance: The STEP trials

Springer Medicine

Zirkulierende HPV-Tumor-DNA als möglicher Biomarker in der Rezidivdiagnostik des HPV-assoziierten Oropharynxkarzinoms

Auszug

At a glance: The STEP trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 7/2020

Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer

Duration-dependent margins for prostate radiotherapy—a practical motion mitigation strategy

Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities

Intensitätsmodulierte fraktionierte Radiotherapie vs. körperstereotaktische Radiotherapie des Prostatakarzinoms (PACE-B) – akute Toxizität aus einer internationalen, randomisierten Phase-III-Nichtunterlegenheitsstudie

Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer

Association between acute histopathological changes of rectal walls and late radiation proctitis following radiotherapy for prostate cancer+